KRAS and neoplasm: This TCR alongside three other KRAS G12V–reactive TCRs derived from peripheral blood T cells of two healthy donors underwent in vitro testing for specificity, cross-reactivity, functional avidity, function in CD4+ T cells (CD8 coreceptor dependency), and tumor cell-line recognition.